All medically important unicellular protozoans cannot synthesize purines de novo and they entirely rely on the purine salvage pathway (PSP) for their nucleotide generation. Therefore, purine derivatives have been considered as a promising source of anti-parasitic compounds since they can act as inhibitors of the PSP enzymes or as toxic products upon their activation inside of the cell. Here, we characterized a Trypanosoma brucei enzyme involved in the salvage of adenine, the adenine phosphoribosyl transferase (APRT). We showed that its two isoforms (APRT1 and APRT2) localize partly in the cytosol and partly in the glycosomes of the bloodstream form (BSF) of the parasite. RNAi silencing of both APRT enzymes showed no major effect on the growth of BSF parasites unless grown in artificial medium with adenine as sole purine source. To add into the portfolio of inhibitors for various PSP enzymes, we designed three types of acyclic nucleotide analogs as potential APRT inhibitors. Out of fifteen inhibitors, four compounds inhibited the activity of the recombinant APRT1 with Ki in single µM values. The ANP phosphoramidate membrane-permeable prodrugs showed pronounced anti-trypanosomal activity in a cell-based assay, despite the fact that APRT enzymes are dispensable for T. brucei growth in vitro. While this suggests that the tested ANP prodrugs exert their toxicity by other means in T. brucei, the newly designed inhibitors can be further improved and explored to identify their actual target(s).

Faculty of Science University of South Bohemia Branišovská 31 37005 České Budějovice Czech Republic

Institute of Parasitology Biology Centre Czech Academy of Sciences Branišovská 31 37005 České Budějovice Czech Republic

The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Flemingovo nám 2 166 10 Prague 6 Czech Republic

The School of Chemistry and Molecular Biosciences The University of Queensland Brisbane QLD 4072 Australia

Zobrazit více v PubMed

de Koning HP, Bridges DJ, Burchmore RJ. Purine and pyrimidine transport in pathogenic protozoa: From biology to therapy. FEMS Microbiol. Rev. 2005;29:987–1020. doi: 10.1016/j.femsre.2005.03.004. PubMed DOI

Hulpia F, et al. Structure–activity relationship exploration of 3'-deoxy-7-deazapurine nucleoside analogues as anti-trypanosoma brucei agents. ACS Infect. Dis. 2020;6:2045–2056. doi: 10.1021/acsinfecdis.0c00105. PubMed DOI

Hulpia F, et al. Combining tubercidin and cordycepin scaffolds results in highly active candidates to treat late-stage sleeping sickness. Nat. Commun. 2019;10:5564. doi: 10.1038/s41467-019-13522-6. PubMed DOI PMC

Berg M, et al. Design and evaluation of Trypanosoma brucei metacaspase inhibitors. Bioorg. Med. Chem. Lett. 2010;20:2001–2006. doi: 10.1016/j.bmcl.2010.01.099. PubMed DOI PMC

Bouton J, Maes L, Karalic I, Caljon G, Van Calenbergh S. Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinetoplastid agents. Eur. J. Med. Chem. 2020;212:113101. doi: 10.1016/j.ejmech.2020.113101. PubMed DOI

Dolezelova E, et al. Evaluation of the Trypanosoma brucei 6-oxopurine salvage pathway as a potential target for drug discovery. PLoS Negl. Trop. Dis. 2018;12:e0006301. doi: 10.1371/journal.pntd.0006301. PubMed DOI PMC

Li Q, et al. GMP synthase is essential for viability and infectivity of Trypanosoma brucei despite a redundant purine salvage pathway. Mol. Microbiol. 2015;97:1006–1020. doi: 10.1111/mmi.13083. PubMed DOI PMC

De Clercq E, Holy A. Acyclic nucleoside phosphonates: A key class of antiviral drugs. Nat. Rev. Drug Discov. 2005;4:928–940. doi: 10.1038/nrd1877. PubMed DOI

Groaz E, De Jonghe S. Overview of biologically active nucleoside phosphonates. Front. Chem. 2020;8:616863. doi: 10.3389/fchem.2020.616863. PubMed DOI PMC

De Clercq E. The acyclic nucleoside phosphonates (ANPs): Antonin Holy's legacy. Med. Res. Rev. 2013;33:1278–1303. doi: 10.1002/med.21283. PubMed DOI

Pertusati F, Serpi M, McGuigan C. Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy. Antivir. Chem. Chemother. 2012;22:181–203. doi: 10.3851/IMP2012. PubMed DOI

Mackman RL, Cihlar T. Prodrug strategies in the design of nucleoside and nucleotide antiviral therapeutics. Annu. Rep. Med. Chem. 2004;39:305–321. doi: 10.1016/S0065-7743(04)39023-8. DOI

Cheviet T, Lefebvre-Tournier I, Wein S, Peyrottes S. Plasmodium purine metabolism and its inhibition by nucleoside and nucleotide analogues. J. Med. Chem. 2019;62:8365–8391. doi: 10.1021/acs.jmedchem.9b00182. PubMed DOI

Spacek P, et al. Synthesis and evaluation of asymmetric acyclic nucleoside bisphosphonates as inhibitors of plasmodium falciparum and human hypoxanthine–guanine–(xanthine) phosphoribosyltransferase. J. Med. Chem. 2017;60:7539–7554. doi: 10.1021/acs.jmedchem.7b00926. PubMed DOI

Spacek P, et al. Synthesis and evaluation of symmetric acyclic nucleoside bisphosphonates as inhibitors of the Plasmodium falciparum, Plasmodium vivax and human 6-oxopurine phosphoribosyltransferases and the antimalarial activity of their prodrugs. Bioorg. Med. Chem. 2017;25:4008–4030. doi: 10.1016/j.bmc.2017.05.048. PubMed DOI

Teran D. Acyclic nucleoside phosphonates as possible chemotherapeutics against Trypanosoma brucei. Drug Discov. Today. 2020;25:1043–1053. doi: 10.1016/j.drudis.2020.02.008. PubMed DOI

Teran D, et al. Crystal structures of Trypanosoma brucei hypoxanthine–guanine–xanthine phosphoribosyltransferase in complex with IMP, GMP and XMP. FEBS J. 2019;286:4721–4736. doi: 10.1111/febs.14987. PubMed DOI

Teran D, et al. Crystal structures and inhibition of Trypanosoma brucei hypoxanthine–guanine phosphoribosyltransferase. Sci. Rep. 2016;6:35894. doi: 10.1038/srep35894. PubMed DOI PMC

Vodnala M, et al. Adenosine kinase mediates high affinity adenosine salvage in Trypanosoma brucei. J. Biol. Chem. 2008;283:5380–5388. doi: 10.1074/jbc.M705603200. PubMed DOI

Luscher A, Onal P, Schweingruber AM, Maser P. Adenosine kinase of Trypanosoma brucei and its role in susceptibility to adenosine antimetabolites. Antimicrob. Agents Chemother. 2007;51:3895–3901. doi: 10.1128/AAC.00458-07. PubMed DOI PMC

Berg M, et al. Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis. Antimicrob. Agents Chemother. 2010;54:1900–1908. doi: 10.1128/AAC.01787-09. PubMed DOI PMC

Luscher A, Lamprea-Burgunder E, Graf FE, de Koning HP, Maser P. Trypanosoma brucei adenine-phosphoribosyltransferases mediate adenine salvage and aminopurinol susceptibility but not adenine toxicity. Int. J. Parasitol. Drugs Drug Resist. 2014;4:55–63. doi: 10.1016/j.ijpddr.2013.12.001. PubMed DOI PMC

Vertommen D, et al. Differential expression of glycosomal and mitochondrial proteins in the two major life-cycle stages of Trypanosoma brucei. Mol. Biochem. Parasitol. 2008;158:189–201. doi: 10.1016/j.molbiopara.2007.12.008. PubMed DOI

Dean S, Sunter JD, Wheeler RJ. TrypTag.org: A trypanosome genome-wide protein localisation resource. Trends Parasitol. 2017;33:80–82. doi: 10.1016/j.pt.2016.10.009. PubMed DOI PMC

Boitz JM, Ullman B, Jardim A, Carter NS. Purine salvage in Leishmania: Complex or simple by design? Trends Parasitol. 2012;28:345–352. doi: 10.1016/j.pt.2012.05.005. PubMed DOI PMC

Hirumi H, Hirumi K. Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J. Parasitol. 1989;75:985–989. doi: 10.2307/3282883. PubMed DOI

Vodnala M, Ranjbarian F, Pavlova A, de Koning HP, Hofer A. Trypanosoma brucei methylthioadenosine phosphorylase protects the parasite from the antitrypanosomal effect of deoxyadenosine: Implications for the pharmacology of adenosine antimetabolites. J. Biol. Chem. 2016;291:11717–11726. doi: 10.1074/jbc.M116.715615. PubMed DOI PMC

Geiser F, Luscher A, de Koning HP, Seebeck T, Maser P. Molecular pharmacology of adenosine transport in Trypanosoma brucei: P1/P2 revisited. Mol. Pharmacol. 2005;68:589–595. doi: 10.1124/mol.104.010298. PubMed DOI

Cesnek M, et al. Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines: Evaluation of their ability to act as inhibitors of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine–guanine–(xanthine) phosphoribosyltransferases. Bioorg. Med. Chem. 2012;20:1076–1089. doi: 10.1016/j.bmc.2011.11.034. PubMed DOI

Keough DT, et al. Aza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, Plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their prodrugs as antimalarial agents. J. Med. Chem. 2015;58:827–846. doi: 10.1021/jm501416t. PubMed DOI

Klejch T, et al. Sulfide, sulfoxide and sulfone bridged acyclic nucleoside phosphonates as inhibitors of the Plasmodium falciparum and human 6-oxopurine phosphoribosyltransferases: Synthesis and evaluation. Eur. J. Med. Chem. 2019;183:111667. doi: 10.1016/j.ejmech.2019.111667. PubMed DOI

Hockova D, et al. N-Branched acyclic nucleoside phosphonates as monomers for the synthesis of modified oligonucleotides. Org. Biomol. Chem. 2015;13:4449–4458. doi: 10.1039/c4ob02265c. PubMed DOI

Hockova D, et al. Synthesis of novel N-branched acyclic nucleoside phosphonates as potent and selective inhibitors of human, Plasmodium falciparum and Plasmodium vivax 6-oxopurine phosphoribosyltransferases. J. Med. Chem. 2012;55:6209–6223. doi: 10.1021/jm300662d. PubMed DOI

Eng WS, et al. First crystal structures of Mycobacterium tuberculosis 6-oxopurine phosphoribosyltransferase: Complexes with GMP and pyrophosphate and with acyclic nucleoside phosphonates whose prodrugs have antituberculosis activity. J. Med. Chem. 2015;58:4822–4838. doi: 10.1021/acs.jmedchem.5b00611. PubMed DOI

Hockova D, Holy A, Andrei G, Snoeck R, Balzarini J. Acyclic nucleoside phosphonates with a branched 2-(2-phosphonoethoxy)ethyl chain: Efficient synthesis and antiviral activity. Bioorg. Med. Chem. 2011;19:4445–4453. doi: 10.1016/j.bmc.2011.06.045. PubMed DOI PMC

Vrbkova S, Dracinsky M, Holy A. Bifunctional acyclic nucleoside phosphonates: 2. Symmetrical 2-{[bis(phosphono)methoxy]methyl}ethyl derivatives of purines and pyrimidines. Collect. Czech. Chem. C. 2007;72:965–983. doi: 10.1135/cccc20070965. DOI

Keough DT, et al. Acyclic nucleoside phosphonates containing a second phosphonate group are potent inhibitors of 6-oxopurine phosphoribosyltransferases and have antimalarial activity. J. Med. Chem. 2013;56:2513–2526. doi: 10.1021/jm301893b. PubMed DOI

Hockova D, et al. Antimalarial activity of prodrugs of N-branched acyclic nucleoside phosphonate inhibitors of 6-oxopurine phosphoribosyltransferases. Bioorg. Med. Chem. 2015;23:5502–5510. doi: 10.1016/j.bmc.2015.07.038. PubMed DOI

Pradere U, Garnier-Amblard EC, Coats SJ, Amblard F, Schinazi RF. Synthesis of nucleoside phosphate and phosphonate prodrugs. Chem. Rev. 2014;114:9154–9218. doi: 10.1021/cr5002035. PubMed DOI PMC

Bashor C, Denu JM, Brennan RG, Ullman B. Kinetic mechanism of adenine phosphoribosyltransferase from Leishmania donovani. Biochemistry. 2002;41:4020–4031. doi: 10.1021/bi0158730. PubMed DOI

Mayclin, S. J., Dranow, D. M., Lorimer, D. D. & Edwards, T. E. Crystal structure of adenine phosphoribosyl transferase from Trypanosoma brucei in complex with AMP, pyrophosphate, and ribose-5-phosphate. PDB ID: 5VN4. 10.2210/pdb5VN4/pdb.

Silva M, Silva CH, Iulek J, Oliva G, Thiemann OH. Crystal structure of adenine phosphoribosyltransferase from Leishmania tarentolae: Potential implications for APRT catalytic mechanism. Biochim. Biophys. Acta. 2004;1696:31–39. doi: 10.1016/j.bbapap.2003.09.003. PubMed DOI

Silva M, Silva CH, Iulek J, Thiemann OH. Three-dimensional structure of human adenine phosphoribosyltransferase and its relation to DHA-urolithiasis. Biochemistry. 2004;43:7663–7671. doi: 10.1021/bi0360758. PubMed DOI

Keough DT, Brereton IM, de Jersey J, Guddat LW. The crystal structure of free human hypoxanthine–guanine phosphoribosyltransferase reveals extensive conformational plasticity throughout the catalytic cycle. J. Mol. Biol. 2005;351:170–181. doi: 10.1016/j.jmb.2005.05.061. PubMed DOI

Wiemer AJ, Wiemer DF. Prodrugs of phosphonates and phosphates: Crossing the membrane barrier. Top. Curr. Chem. 2015;360:115–160. doi: 10.1007/128_2014_561. PubMed DOI PMC

Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997;267:727–748. doi: 10.1006/jmbi.1996.0897. PubMed DOI

Moriarty NW, Grosse-Kunstleve RW, Adams PD. electronic Ligand Builder and Optimization Workbench (eLBOW): A tool for ligand coordinate and restraint generation. Acta Crystallogr. D Biol. Crystallogr. 2009;65:1074–1080. doi: 10.1107/S0907444909029436. PubMed DOI PMC

Korb O, Stutzle T, Exner TE. Empirical scoring functions for advanced protein-ligand docking with plants. J. Chem. Inf. Model. 2009;49:84–96. doi: 10.1021/ci800298z. PubMed DOI

Schrodinger, L. L. C. The PyMOL Molecular GraphicsSystem, Version, X.X. (2010).

Wickstead B, Ersfeld K, Gull K. Targeting of a tetracycline-inducible expression system to the transcriptionally silent minichromosomes of Trypanosoma brucei. Mol. Biochem. Parasitol. 2002;125:211–216. doi: 10.1016/S0166-6851(02)00238-4. PubMed DOI

Panigrahi AK, et al. Mitochondrial complexes in Trypanosoma brucei: A novel complex and a unique oxidoreductase complex. Mol. Cell Proteomics. 2008;7:534–545. doi: 10.1074/mcp.M700430-MCP200. PubMed DOI

Benz C, Dondelinger F, McKean PG, Urbaniak MD. Cell cycle synchronisation of Trypanosoma brucei by centrifugal counter-flow elutriation reveals the timing of nuclear and kinetoplast DNA replication. Sci. Rep. 2017;7:17599. doi: 10.1038/s41598-017-17779-z. PubMed DOI PMC

Repurposing of MitoTam: Novel Anti-Cancer Drug Candidate Exhibits Potent Activity against Major Protozoan and Fungal Pathogens

Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects